Study on Next Generation Antibody Drug Conjugate Developed by Centrose Reveals Strong Efficacy in Human Cancer Models

Share Article

Precise antibody drug delivery has entered a totally new level where now a potent drug can be positioned within angstroms of its target, decreasing off-target side effects. The first results of an EDC (Extracellular Drug Conjugate) were published showing significant activity against head and neck cancers.

CENTROSE, the leader in EDC Technology, announced the publication of the first EDC scientific article. The article published today in the journal “Oral Oncology” and entitled “A novel extracellular drug conjugate significantly inhibits head and neck cancer squamous cell carcinoma,” demonstrates the potent anti-cancer effects of the company’s EDC technology. The study focused on an EDC with strong killing activity toward head and neck cancer, a cancer type that remains challenging to treat, with poor survival and high morbidity, thus demanding new therapeutic avenues.

The University of Alabama at Birmingham’s (UAB) oncology research group led by Dr. Eben Rosenthal conducted the study. The full team, which included Centrose staff, concluded that in the models tested, the EDC was a potent inhibitor of HNSCC with activity surpassing standard of care. “I believe this technology has real promise”, states Dr. Rosenthal.

The publication adds to a growing body of scientific research demonstrating the significant promise of targeting small molecule drugs to extracellular targets with EDC Technology. Centrose pioneered EDC Technology in order to discover and develop safer and more effective therapies that improve patient health.

“This UAB publication is an important step showing that EDC Technology works well in the hands of others,” stated Dr. James Prudent. “It will be exciting when our other expert collaborators also begin to publish on EDC Technology as we have literally just begun to scratch the surface.”

Exclusive to Centrose, EDC Technology is a “first in class” next generation antibody drug conjugate (ADC) technology. Unlike ADCs, EDCs act on multi-protein complexes at the cell surface and thus do not require internalization. This makes them safer and more potent. In addition, because not all surface proteins internalize efficiently, EDC Technology can employ antibodies not applicable to ADCs.

Recently, Centrose also determined that its lead drug (EDC1) kills cancer at cancer’s deadliest phase – the metastatic phase. EDC1 does this by acting on a cell surface multi-protein complex that forms when cells become mobile and drug resistant.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. James Prudent
Email >
Visit website